Histone deacetylase inhibitors: a novel class of anti-cancer agents on its way to the market.

[1]  J. Auwerx,et al.  Sirtuin functions in health and disease. , 2007, Molecular endocrinology.

[2]  Yukihiro Itoh,et al.  Design, synthesis, and biological activity of folate receptor-targeted prodrugs of thiolate histone deacetylase inhibitors. , 2007, Bioorganic & medicinal chemistry letters.

[3]  V. Richon,et al.  Aminosuberoyl hydroxamic acids (ASHAs): a potent new class of HDAC inhibitors. , 2007, Bioorganic & medicinal chemistry letters.

[4]  M. Grunstein,et al.  Functions of site-specific histone acetylation and deacetylation. , 2007, Annual review of biochemistry.

[5]  J. Kell.  Drug evaluation: MGCD-0103, a histone deacetylase inhibitor for the treatment of cancer. , 2007, Current opinion in investigational drugs.

[6]  M. Caraglia,et al.  Histone deacetylase inhibitors: a new wave of molecular targeted anticancer agents. , 2007, Recent patents on anti-cancer drug discovery.

[7]  David Sinclair,et al.  Sirtuins in mammals: insights into their biological function. , 2007, The Biochemical journal.

[8]  Eric Verdin,et al.  Design and evaluation of 'Linkerless' hydroxamic acids as selective HDAC8 inhibitors. , 2007, Bioorganic & medicinal chemistry letters.

[9]  Ky-Youb Nam,et al.  Structure−Activity Relationship Studies of a Series of Novel δ-Lactam-Based Histone Deacetylase Inhibitors , 2007 .

[10]  Dong Hoon Kim,et al.  Anti-tumor activity of N-hydroxy-7-(2-naphthylthio) heptanomide, a novel histone deacetylase inhibitor. , 2007, Biochemical and biophysical research communications.

[11]  R. Johnstone,et al.  Histone deacetylase inhibitors in cancer therapy , 2007, Expert opinion on investigational drugs.

[12]  M. K. Pflum,et al.  Structural requirements of HDAC inhibitors: SAHA analogs functionalized adjacent to the hydroxamic acid. , 2007, Bioorganic & medicinal chemistry letters.

[13]  Tao Liu,et al.  Design and synthesis of a potent histone deacetylase inhibitor. , 2007, Journal of medicinal chemistry.

[14]  M. Esteller.  Cancer epigenomics: DNA methylomes and histone-modification maps , 2007, Nature Reviews Genetics.

[15]  D. Marchion,et al.  Development of histone deacetylase inhibitors for cancer treatment , 2007, Expert review of anticancer therapy.

[16]  C. Monneret.  Histone deacetylase inhibitors for epigenetic therapy of cancer , 2007, Anti-cancer drugs.

[17]  Marvin J Miller,et al.  Syntheses of amamistatin fragments and determination of their HDAC and antitumor activity. , 2007, Organic letters.

[18]  Yukihiro Itoh,et al.  Identification of a potent and stable antiproliferative agent by the prodrug formation of a thiolate histone deacetylase inhibitor. , 2007, Bioorganic & medicinal chemistry letters.

[19]  D. Bates,et al.  Crystal structure of a conserved N-terminal domain of histone deacetylase 4 reveals functional insights into glutamine-rich domains , 2007, Proceedings of the National Academy of Sciences.

[20]  Hiroyuki Suzuki,et al.  HDAC2 controls IgM H‐ and L‐chain gene expressions via EBF1, Pax5, Ikaros, Aiolos and E2A gene expressions , 2007, Genes to cells : devoted to molecular & cellular mechanisms.

[21]  Michele Pallaoro,et al.  HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics , 2007, Cell Research.

[22]  A. Mai,et al.  Discovery of uracil-based histone deacetylase inhibitors able to reduce acquired antifungal resistance and trailing growth in Candida albicans. , 2007, Bioorganic & medicinal chemistry letters.

[23]  Peter A. Jones,et al.  The Epigenomics of Cancer , 2007, Cell.

[24]  T. Kouzarides.  Chromatin Modifications and Their Function , 2007, Cell.

[25]  D. Tremethick,et al.  Higher-Order Structures of Chromatin: The Elusive 30 nm Fiber , 2007, Cell.

[26]  G. Bifulco,et al.  Molecular insights into azumamide e histone deacetylases inhibitory activity. , 2007, Journal of the American Chemical Society.

[27]  A. Ganesan,et al.  Total synthesis of azumamide A and azumamide E, evaluation as histone deacetylase inhibitors, and design of a more potent analogue. , 2007, Organic letters.

[28]  C. Bradbury,et al.  Cross-talk between Histone Modifications in Response to Histone Deacetylase Inhibitors , 2007, Journal of Biological Chemistry.

[29]  Steve Price,et al.  Identification and optimisation of a series of substituted 5-(1H-pyrazol-3-yl)-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors. , 2007, Bioorganic & medicinal chemistry letters.

[30]  K. Garber.  HDAC inhibitors overcome first hurdle , 2007, Nature Biotechnology.

[31]  Minghong Xu,et al.  Histone Deacetylase 3 Interacts with and Deacetylates Myocyte Enhancer Factor 2 , 2006, Molecular and Cellular Biology.

[32]  Michael Rowley,et al.  A series of novel, potent, and selective histone deacetylase inhibitors. , 2006, Bioorganic & medicinal chemistry letters.

[33]  A. Ganesan,et al.  Azumamides A-E: histone deacetylase inhibitory cyclic tetrapeptides from the marine sponge Mycale izuensis. , 2006, Angewandte Chemie.

[34]  Y. Hashimoto,et al.  Design, synthesis, and evaluation of cyclic amide/imide-bearing hydroxamic acid derivatives as class-selective histone deacetylase (HDAC) inhibitors. , 2006, Bioorganic & medicinal chemistry.

[35]  J. Moss,et al.  The 39-kDa poly(ADP-ribose) glycohydrolase ARH3 hydrolyzes O-acetyl-ADP-ribose, a product of the Sir2 family of acetyl-histone deacetylases , 2006, Proceedings of the National Academy of Sciences.

[36]  C. Charrier,et al.  Synthesis of rigid trichostatin A analogs as HDAC inhibitors. , 2006, Bioorganic & medicinal chemistry letters.

[37]  A. Kim,et al.  Histone deacetylase 1-mediated histone modification regulates osteoblast differentiation. , 2006, Molecular endocrinology.

[38]  Philip Smith,et al.  Breast Cancer Metastasis Suppressor 1 Functions as a Corepressor by Enhancing Histone Deacetylase 1-Mediated Deacetylation of RelA/p65 and Promoting Apoptosis , 2006, Molecular and Cellular Biology.

[39]  G. Giannini,et al.  Exploring alternative Zn-binding groups in the design of HDAC inhibitors: squaric acid, N-hydroxyurea, and oxazoline analogues of SAHA. , 2006, Bioorganic & medicinal chemistry letters.

[40]  L. Altucci,et al.  Synthesis and biological properties of novel, uracil-containing histone deacetylase inhibitors. , 2006, Journal of medicinal chemistry.

[41]  Sang Gyun Kim,et al.  Antitumor activity of SK-7041, a novel histone deacetylase inhibitor, in human lung and breast cancer cells. , 2006, Anticancer research.

[42]  S. Kulp,et al.  Antitumor Effects of a Novel Phenylbutyrate-Based Histone Deacetylase Inhibitor, (S)-HDAC-42, in Prostate Cancer , 2006, Clinical Cancer Research.

[43]  Jessica E. Bolden,et al.  Anticancer activities of histone deacetylase inhibitors , 2006, Nature Reviews Drug Discovery.

[44]  G. Han,et al.  Synthesis, enzymatic inhibition, and cancer cell growth inhibition of novel delta-lactam-based histone deacetylase (HDAC) inhibitors. , 2006, Bioorganic & medicinal chemistry letters.

[45]  A. Kalita,et al.  Substituted N-(2-aminophenyl)-benzamides, (E)-N-(2-aminophenyl)-acrylamides and their analogues: novel classes of histone deacetylase inhibitors. , 2006, Bioorganic & medicinal chemistry letters.

[46]  V. Kulkarni,et al.  3D-QSAR of histone deacetylase inhibitors: hydroxamate analogues. , 2006, Organic & biomolecular chemistry.

[47]  Yukihiro Itoh,et al.  Highly potent and selective histone deacetylase 6 inhibitors designed based on a small-molecular substrate. , 2006, Journal of medicinal chemistry.

[48]  Hsiang-Yu Lin,et al.  Targeting histone deacetylase in cancer therapy , 2006, Medicinal research reviews.

[49]  Jack R. Davis,et al.  CRA-026440: a potent, broad-spectrum, hydroxamic histone deacetylase inhibitor with antiproliferative and antiangiogenic activity in vitro and in vivo , 2006, Molecular Cancer Therapeutics.

[50]  P. Gottlieb,et al.  Identification and characterization of Smyd2: a split SET/MYND domain-containing histone H3 lysine 36-specific methyltransferase that interacts with the Sin3 histone deacetylase complex , 2006, Molecular Cancer.

[51]  J. Boeke,et al.  The biochemistry of sirtuins. , 2006, Annual review of biochemistry.

[52]  A. Ouaissi,et al.  Histone Deacetylase Enzymes as Potential Drug Targets in Cancer and Parasitic Diseases , 2006, Journal of biomedicine & biotechnology.

[53]  G. Kong,et al.  Potent in vivo anti-breast cancer activity of IN-2001, a novel inhibitor of histone deacetylase, in MMTV/c-Neu mice. , 2006, Cancer research.

[54]  F. Alt,et al.  SirT2 is a histone deacetylase with preference for histone H4 Lys 16 during mitosis. , 2006, Genes & development.

[55]  Minoru Yoshida,et al.  Chlamydocin analogs bearing carbonyl group as possible ligand toward zinc atom in histone deacetylases. , 2006, Bioorganic & medicinal chemistry.

[56]  C. Horvath,et al.  Carbonyl- and sulfur-containing analogs of suberoylanilide hydroxamic acid: Potent inhibition of histone deacetylases. , 2006, Bioorganic & medicinal chemistry.

[57]  Takayoshi Suzuki,et al.  Rational design of non-hydroxamate histone deacetylase inhibitors. , 2006, Mini reviews in medicinal chemistry.

[58]  Z. Cao,et al.  CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo , 2006, Molecular Cancer Therapeutics.

[59]  Louise Fairall,et al.  EM measurements define the dimensions of the "30-nm" chromatin fiber: evidence for a compact, interdigitated structure. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[60]  L. Gomez‐Paloma,et al.  Chemistry and biology of chromatin remodeling agents: state of art and future perspectives of HDAC inhibitors. , 2006, Current medicinal chemistry.

[61]  Silvio Massa,et al.  3-D QSAR Studies on Histone Deacetylase Inhibitors. A GOLPE/GRID Approach on Different Series of Compounds , 2006, J. Chem. Inf. Model..

[62]  K. Shin‐ya,et al.  A total synthesis of spiruchostatin A , 2006 .

[63]  A. Mai,et al.  Aroyl‐Pyrrolyl Hydroxyamides: Influence of Pyrrole C4‐Phenylacetyl Substitution on Histone Deacetylase Inhibition , 2006, ChemMedChem.

[64]  M. Pazin,et al.  Histone H4-K16 Acetylation Controls Chromatin Structure and Protein Interactions , 2006, Science.

[65]  Ø. Bruserud,et al.  Protein lysine acetylation in normal and leukaemic haematopoiesis: HDACs as possible therapeutic targets in adult AML , 2006, Expert opinion on therapeutic targets.

[66]  A. Papavassiliou,et al.  FK228 (depsipeptide): a HDAC inhibitor with pleiotropic antitumor activities , 2006, Cancer Chemotherapy and Pharmacology.

[67]  D. Qian,et al.  Targeting Tumor Angiogenesis with Histone Deacetylase Inhibitors: the Hydroxamic Acid Derivative LBH589 , 2006, Clinical Cancer Research.

[68]  G. Bifulco,et al.  Total synthesis, NMR solution structure, and binding model of the potent histone deacetylase inhibitor FR235222. , 2006, Angewandte Chemie.

[69]  Sharon Y. R. Dent,et al.  Histone modifying enzymes and cancer: Going beyond histones , 2005, Journal of cellular biochemistry.

[70]  H. Weinmann,et al.  Histone deacetylase inhibitors: a survey of recent patents , 2005 .

[71]  A. Mai,et al.  Exploring the connection unit in the HDAC inhibitor pharmacophore model: novel uracil-based hydroxamates. , 2005, Bioorganic & medicinal chemistry letters.

[72]  Takayoshi Suzuki,et al.  Non-hydroxamate histone deacetylase inhibitors. , 2005, Current medicinal chemistry.

[73]  Y. Hashimoto,et al.  Design and synthesis of phthalimide-type histone deacetylase inhibitors. , 2005, Bioorganic & medicinal chemistry letters.

[74]  O. Wiest,et al.  Toward selective histone deacetylase inhibitor design: homology modeling, docking studies, and molecular dynamics simulations of human class I histone deacetylases. , 2005, Journal of medicinal chemistry.

[75]  A. Sparreboom,et al.  Rational Development of Histone Deacetylase Inhibitors as Anticancer Agents: A Review , 2005, Molecular Pharmacology.

[76]  V. Sartorelli,et al.  Mechanisms underlying the transcriptional regulation of skeletal myogenesis. , 2005, Current opinion in genetics & development.

[77]  A. Ho,et al.  Chromosomal organization and localization of the novel class IV human histone deacetylase 11 gene. , 2005, International journal of molecular medicine.

[78]  Yan-shen Guo,et al.  Exploration of a binding mode of indole amide analogues as potent histone deacetylase inhibitors and 3D-QSAR analyses. , 2005, Bioorganic & medicinal chemistry.

[79]  C. Maroun,et al.  Histone deacetylase inhibitors: latest developments, trends and prospects. , 2005, Current medicinal chemistry. Anti-cancer agents.

[80]  C. Chen,et al.  Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. , 2005, Journal of medicinal chemistry.

[81]  Takayoshi Suzuki,et al.  Design and synthesis of non-hydroxamate histone deacetylase inhibitors: identification of a selective histone acetylating agent. , 2005, Bioorganic & medicinal chemistry.

[82]  P. Finn,et al.  Novel sulfonamide derivatives as inhibitors of histone deacetylase , 2005 .

[83]  Kevin Struhl,et al.  Heterochromatin formation involves changes in histone modifications over multiple cell generations , 2005, The EMBO journal.

[84]  M. Janicot,et al.  Discovery of pyrimidyl-5-hydroxamic acids as new potent histone deacetylase inhibitors. , 2005, European journal of medicinal chemistry.

[85]  Minoru Yoshida,et al.  HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. , 2005, Molecular cell.

[86]  D. Pei,et al.  Total synthesis of cyclic tetrapeptide FR235222, a potent immunosuppressant that inhibits mammalian histone deacetylases. , 2005, Organic letters.

[87]  M. Lazar,et al.  The histone‐binding code of nuclear receptor co‐repressors matches the substrate specificity of histone deacetylase 3 , 2005, EMBO reports.

[88]  Sampathkumar Anandan,et al.  Mercaptoamide-based non-hydroxamic acid type histone deacetylase inhibitors. , 2005, Bioorganic & medicinal chemistry letters.

[89]  L. Altucci,et al.  Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamides. , 2005, Journal of medicinal chemistry.

[90]  E. Seto,et al.  Histone deacetylase 3 (HDAC3) activity is regulated by interaction with protein serine/threonine phosphatase 4. , 2005, Genes & development.

[91]  M. Fraga,et al.  Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer , 2005, Nature Genetics.

[92]  M. Jung,et al.  Chemistry and biology of mercaptoacetamides as novel histone deacetylase inhibitors. , 2005, Bioorganic & medicinal chemistry letters.

[93]  P. Marks,et al.  Drug Insight: histone deacetylase inhibitors—development of the new targeted anticancer agent suberoylanilide hydroxamic acid , 2005, Nature Clinical Practice Oncology.

[94]  R. Panettieri,et al.  Anaphylatoxin C3a receptors in asthma , 2005, Respiratory research.

[95]  Takayoshi Suzuki,et al.  Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates. , 2005, Journal of medicinal chemistry.

[96]  Takayoshi Suzuki,et al.  Identification of a potent non-hydroxamate histone deacetylase inhibitor by mechanism-based drug design. , 2005, Bioorganic & medicinal chemistry letters.

[97]  J. Issa,et al.  Histone Deacetylase Inhibitors: A Review of Their Clinical Status as Antineoplastic Agents , 2005, Cancer investigation.

[98]  Minoru Yoshida,et al.  Chlamydocin-hydroxamic acid analogues as histone deacetylase inhibitors. , 2004, Bioorganic & medicinal chemistry.

[99]  R. Marmorstein.  Structure and chemistry of the Sir2 family of NAD+-dependent histone/protein deactylases. , 2004, Biochemical Society transactions.

[100]  Minoru Yoshida,et al.  Novel histone deacetylase inhibitors: cyclic tetrapeptide with trifluoromethyl and pentafluoroethyl ketones. , 2004, Bioorganic & medicinal chemistry letters.

[101]  M. Curtin.  Synthesis of novel hydroxamate and non-hydroxamate histone deacetylase inhibitors. , 2004, Current opinion in drug discovery & development.

[102]  R. De Francesco,et al.  Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[103]  D. Reinberg,et al.  Human SirT1 interacts with histone H1 and promotes formation of facultative heterochromatin. , 2004, Molecular cell.

[104]  E. Olson,et al.  Histone Deacetylases 5 and 9 Govern Responsiveness of the Heart to a Subset of Stress Signals and Play Redundant Roles in Heart Development , 2004, Molecular and Cellular Biology.

[105]  P. Karplus,et al.  A Novel Mechanism of Chemoprotection by Sulforaphane , 2004, Cancer Research.

[106]  S. Uesato,et al.  Potent histone deacetylase inhibitors: N-hydroxybenzamides with antitumor activities. , 2004, Bioorganic & medicinal chemistry.

[107]  B. Schultz,et al.  Kinetics and comparative reactivity of human class I and class IIb histone deacetylases. , 2004, Biochemistry.

[108]  Sang Gyun Kim,et al.  Class I Histone Deacetylase-Selective Novel Synthetic Inhibitors Potently Inhibit Human Tumor Proliferation , 2004, Clinical Cancer Research.

[109]  C. Peterson,et al.  Histones and histone modifications , 2004, Current Biology.

[110]  C. MacKintosh,et al.  Dynamic interactions between 14-3-3 proteins and phosphoproteins regulate diverse cellular processes. , 2004, The Biochemical journal.

[111]  J. R. Somoza,et al.  Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. , 2004, Structure.

[112]  A. Kohara,et al.  Thiol-based SAHA analogues as potent histone deacetylase inhibitors. , 2004, Bioorganic & medicinal chemistry letters.

[113]  M. Caraglia,et al.  Acetylation of proteins as novel target for antitumor therapy: Review article , 2004, Amino Acids.

[114]  L. Guarente,et al.  The Sir2 family of protein deacetylases. , 2004, Annual review of biochemistry.

[115]  Thomas A. Miller.  Patent status of histone deacetylase inhibitors , 2004 .

[116]  A. Ehrenhofer-Murray,et al.  Chromatin dynamics at DNA replication, transcription and repair. , 2004, European journal of biochemistry.

[117]  Vera Rogiers,et al.  Trichostatin A-like hydroxamate histone deacetylase inhibitors as therapeutic agents: toxicological point of view. , 2004, Current medicinal chemistry.

[118]  O. Wiest,et al.  On the function of the 14 A long internal cavity of histone deacetylase-like protein: implications for the design of histone deacetylase inhibitors. , 2004, Journal of medicinal chemistry.

[119]  S. Hiebert,et al.  Role of RUNX family members in transcriptional repression and gene silencing , 2004, Oncogene.

[120]  D. Vigushin,et al.  Stereodefined and polyunsaturated inhibitors of histone deacetylase based on (2E,4E)-5-arylpenta-2,4-dienoic acid hydroxyamides. , 2004, Bioorganic & medicinal chemistry letters.

[121]  Minoru Yoshida,et al.  Synthesis and histone deacetylase inhibitory activity of cyclic tetrapeptides containing a retrohydroxamate as zinc ligand. , 2004, Bioorganic & medicinal chemistry letters.

[122]  Leming Shi,et al.  Quantitative structure-activity relationship study of histone deacetylase inhibitors. , 2004, Current medicinal chemistry. Anti-cancer agents.

[123]  D. Fairlie,et al.  Antiproliferative and phenotype-transforming antitumor agents derived from cysteine. , 2004, Journal of Medicinal Chemistry.

[124]  Ivan V. Gregoretti,et al.  Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. , 2004, Journal of molecular biology.

[125]  G. Almouzni,et al.  Histone chaperones, a supporting role in the limelight. , 2004, Biochimica et biophysica acta.

[126]  J. Qin,et al.  Components of a Pathway Maintaining Histone Modification and Heterochromatin Protein 1 Binding at the Pericentric Heterochromatin in Mammalian Cells* , 2004, Journal of Biological Chemistry.

[127]  J. Workman,et al.  In Vitro Targeting Reveals Intrinsic Histone Tail Specificity of the Sin3/Histone Deacetylase and N-CoR/SMRT Corepressor Complexes , 2004, Molecular and Cellular Biology.

[128]  Silvio Massa,et al.  3-(4-Aroyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-propenamides as a New Class of Synthetic Histone Deacetylase Inhibitors. 2. Effect of Pyrrole-C2 and/or -C4 Substitutions on Biological Activity† , 2004 .

[129]  A. Mai,et al.  3-(4-Aroyl-1-methyl-1H-pyrrol-2-yl)-N-hydroxy-2-propenamides as a new class of synthetic histone deacetylase inhibitors. 3. Discovery of novel lead compounds through structure-based drug design and docking studies. , 2004, Journal of medicinal chemistry.

[130]  A. Ganesan,et al.  Total synthesis of spiruchostatin A, a potent histone deacetylase inhibitor. , 2004, Journal of the American Chemical Society.

[131]  A. Kalita,et al.  (2-Amino-phenyl)-amides of ω-substituted alkanoic acids as new histone deacetylase inhibitors , 2004 .

[132]  A. Kohara,et al.  Novel histone deacetylase inhibitors: design, synthesis, enzyme inhibition, and binding mode study of SAHA-based non-hydroxamates. , 2003, Bioorganic & medicinal chemistry letters.

[133]  J. Vance,et al.  The Deacetylase HDAC6 Regulates Aggresome Formation and Cell Viability in Response to Misfolded Protein Stress , 2003, Cell.

[134]  Minoru Yoshida,et al.  Cyclic tetrapeptides bearing a sulfhydryl group potently inhibit histone deacetylases. , 2003, Organic letters.

[135]  J. Y. Lee,et al.  Synthesis and biological evaluation of 3-(4-substituted-phenyl)-N-hydroxy-2-propenamides, a new class of histone deacetylase inhibitors. , 2003, Journal of medicinal chemistry.

[136]  K. Glaser,et al.  Heterocyclic ketones as inhibitors of histone deacetylase. , 2003, Bioorganic & medicinal chemistry letters.

[137]  A. Mai,et al.  Discovery of (aryloxopropenyl)pyrrolyl hydroxyamides as selective inhibitors of class IIa histone deacetylase homologue HD1-A. , 2003, Journal of medicinal chemistry.

[138]  K. Glaser,et al.  Histone deacetylase inhibitors: the Abbott experience. , 2003, Current medicinal chemistry.

[139]  Daniel Delorme,et al.  Novel hydroxamate and anilide derivatives as potent histone deacetylase inhibitors: synthesis and antiproliferative evaluation. , 2003, Current medicinal chemistry.

[140]  S. Minucci,et al.  Involvement of the Histone Deacetylase SIRT1 in Chicken Ovalbumin Upstream Promoter Transcription Factor (COUP-TF)-interacting Protein 2-mediated Transcriptional Repression* , 2003, Journal of Biological Chemistry.

[141]  S. Remiszewski.  The discovery of NVP-LAQ824: from concept to clinic. , 2003, Current medicinal chemistry.

[142]  J. Arts,et al.  Histone deacetylase inhibitors: from chromatin remodeling to experimental cancer therapeutics. , 2003, Current medicinal chemistry.

[143]  Paul L. Richardson,et al.  α-Keto amides as inhibitors of histone deacetylase , 2003 .

[144]  N. Lehming,et al.  Global effects of histone modifications. , 2003, Briefings in functional genomics & proteomics.

[145]  P. Atadja,et al.  N-hydroxy-3-phenyl-2-propenamides as novel inhibitors of human histone deacetylase with in vivo antitumor activity: discovery of (2E)-N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide (NVP-LAQ824). , 2003, Journal of medicinal chemistry.

[146]  F. Alt,et al.  Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[147]  P. Finn,et al.  Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. , 2003, Molecular cancer therapeutics.

[148]  E. Seto,et al.  Phosphorus-based SAHA analogues as histone deacetylase inhibitors. , 2003, Organic letters.

[149]  J. T. Kadonaga,et al.  Chromatin assembly by DNA-translocating motors , 2003, Nature Reviews Molecular Cell Biology.

[150]  M. Lazar,et al.  The N-CoR/Histone Deacetylase 3 Complex Is Required for Repression by Thyroid Hormone Receptor , 2003, Molecular and Cellular Biology.

[151]  R. Roeder,et al.  S Phase Activation of the Histone H2B Promoter by OCA-S, a Coactivator Complex that Contains GAPDH as a Key Component , 2003, Cell.

[152]  Po Zhao,et al.  Sir2 regulates skeletal muscle differentiation as a potential sensor of the redox state. , 2003, Molecular cell.

[153]  S. Elledge,et al.  Multiple Tumor Suppressor Pathways Negatively Regulate Telomerase , 2003, Cell.

[154]  V. Rogiers,et al.  Amide analogues of TSA: synthesis, binding mode analysis and HDAC inhibition. , 2003, Bioorganic & medicinal chemistry letters.

[155]  Yan Guo,et al.  Indole amide hydroxamic acids as potent inhibitors of histone deacetylases. , 2003, Bioorganic & medicinal chemistry letters.

[156]  F. Dequiedt,et al.  Class II histone deacetylases: versatile regulators. , 2003, Trends in genetics : TIG.

[157]  V. Kiermer,et al.  HDAC7, a thymus-specific class II histone deacetylase, regulates Nur77 transcription and TCR-mediated apoptosis. , 2003, Immunity.

[158]  Michael A. Tainsky,et al.  Role for Human SIRT2 NAD-Dependent Deacetylase Activity in Control of Mitotic Exit in the Cell Cycle , 2003, Molecular and Cellular Biology.

[159]  S. Schreiber,et al.  Structural biasing elements for in-cell histone deacetylase paralog selectivity. , 2003, Journal of the American Chemical Society.

[160]  Stuart L Schreiber,et al.  Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[161]  C. Allis,et al.  Modulation of histone acetylation by [4-(acetylamino)-N-(2-amino-phenyl) benzamide] in HCT-8 colon carcinoma. , 2003, Molecular cancer therapeutics.

[162]  Jun Qin,et al.  Purification and functional characterization of the human N‐CoR complex: the roles of HDAC3, TBL1 and TBLR1 , 2003, The EMBO journal.

[163]  A. V. van Kuilenburg,et al.  Histone deacetylases (HDACs): characterization of the classical HDAC family. , 2003, The Biochemical journal.

[164]  P. Matthias,et al.  HDAC‐6 interacts with and deacetylates tubulin and microtubules in vivo , 2003, The EMBO journal.

[165]  Y. Mitani,et al.  Histone Acetylation and Gastrointestinal Carcinogenesis , 2003, Annals of the New York Academy of Sciences.

[166]  Kuang-Hung Cheng,et al.  Histone Deacetylases: Unique Players in Shaping the Epigenetic Histone Code , 2003, Annals of the New York Academy of Sciences.

[167]  G. Gores,et al.  Calpains Can Do It Alone: Implications for Cancer Therapy , 2003, Cancer biology & therapy.

[168]  R. Shiekhattar,et al.  A Candidate X-linked Mental Retardation Gene Is a Component of a New Family of Histone Deacetylase-containing Complexes* , 2003, The Journal of Biological Chemistry.

[169]  Shigehiro Takase,et al.  FR235222, a Fungal Metabolite, is a Novel Immunosuppressant that Inhibits Mammalian Histone Deacetylase (HDAC) , 2003 .

[170]  K. Glaser,et al.  Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. , 2003, Molecular cancer therapeutics.

[171]  K. Luger,et al.  Histone chaperones and nucleosome assembly. , 2003, Current opinion in structural biology.

[172]  J. Denu,et al.  The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase. , 2003, Molecular cell.

[173]  F. Ishikawa,et al.  Human Sir2-related protein SIRT1 associates with the bHLH repressors HES1 and HEY2 and is involved in HES1- and HEY2-mediated transcriptional repression. , 2003, Biochemical and biophysical research communications.

[174]  Daniel Delorme,et al.  Development of potential antitumor agents. Synthesis and biological evaluation of a new set of sulfonamide derivatives as histone deacetylase inhibitors. , 2003, Journal of medicinal chemistry.

[175]  Silvio Massa,et al.  3-(4-Aroyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-alkylamides as a new class of synthetic histone deacetylase inhibitors. 1. Design, synthesis, biological evaluation, and binding mode studies performed through three different docking procedures. , 2003, Journal of medicinal chemistry.

[176]  P. Lansdorp,et al.  The Mammalian SIR2α Protein Has a Role in Embryogenesis and Gametogenesis , 2003, Molecular and Cellular Biology.

[177]  S. Horinouchi,et al.  In vivo destabilization of dynamic microtubules by HDAC6‐mediated deacetylation , 2002, The EMBO journal.

[178]  M. Guenther,et al.  Assembly of the SMRT-histone deacetylase 3 repression complex requires the TCP-1 ring complex. , 2002, Genes & development.

[179]  K. Glaser,et al.  Trifluoromethyl ketones as inhibitors of histone deacetylase. , 2002, Bioorganic & medicinal chemistry letters.

[180]  L. Pemberton,et al.  A role for nucleosome assembly protein 1 in the nuclear transport of histones H2A and H2B , 2002, The EMBO journal.

[181]  Wei Gu,et al.  Acetylation inactivates the transcriptional repressor BCL6 , 2002, Nature Genetics.

[182]  K. Glaser,et al.  Succinimide hydroxamic acids as potent inhibitors of histone deacetylase (HDAC). , 2002, Bioorganic & medicinal chemistry letters.

[183]  A. Feinberg,et al.  SIRT3, a human SIR2 homologue, is an NAD- dependent deacetylase localized to mitochondria , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[184]  E. Olson,et al.  Association of Class II Histone Deacetylases with Heterochromatin Protein 1: Potential Role for Histone Methylation in Control of Muscle Differentiation , 2002, Molecular and Cellular Biology.

[185]  R. Eisenman,et al.  Histone deacetylase 6 binds polyubiquitin through its zinc finger (PAZ domain) and copurifies with deubiquitinating enzymes , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[186]  D. Vigushin.  FR-901228 Fujisawa/National Cancer Institute. , 2002, Current opinion in investigational drugs.

[187]  R. Shiekhattar,et al.  A chromatin remodelling complex that loads cohesin onto human chromosomes , 2002, Nature.

[188]  E. Verdin,et al.  The human silent information regulator (Sir)2 homologue hSIRT3 is a mitochondrial nicotinamide adenine dinucleotide–dependent deacetylase , 2002, The Journal of cell biology.

[189]  A. Kalita,et al.  Sulfonamide anilides, a novel class of histone deacetylase inhibitors, are antiproliferative against human tumors. , 2002, Cancer research.

[190]  Fred Asselbergs,et al.  Cloning and Functional Characterization of HDAC11, a Novel Member of the Human Histone Deacetylase Family* , 2002, The Journal of Biological Chemistry.

[191]  Manfred Jung,et al.  Structure-activity relationships on phenylalanine-containing inhibitors of histone deacetylase: in vitro enzyme inhibition, induction of differentiation, and inhibition of proliferation in Friend leukemic cells. , 2002, Journal of medicinal chemistry.

[192]  Daniel Delorme,et al.  Structurally simple trichostatin A-like straight chain hydroxamates as potent histone deacetylase inhibitors. , 2002, Journal of medicinal chemistry.

[193]  R. Shiekhattar,et al.  A core–BRAF35 complex containing histone deacetylase mediates repression of neuronal-specific genes , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[194]  Xiao-Fan Wang,et al.  HDAC6 is a microtubule-associated deacetylase , 2002, Nature.

[195]  S. Minucci,et al.  Human SIR2 deacetylates p53 and antagonizes PML/p53‐induced cellular senescence , 2002, The EMBO journal.

[196]  J. Tyler.  Chromatin assembly. Cooperation between histone chaperones and ATP-dependent nucleosome remodeling machines. , 2002, European journal of biochemistry.

[197]  C. Peterson.  HDAC's at work: everyone doing their part. , 2002, Molecular cell.

[198]  Silvio Massa,et al.  Binding mode analysis of 3-(4-benzoyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-propenamide: a new synthetic histone deacetylase inhibitor inducing histone hyperacetylation, growth inhibition, and terminal cell differentiation. , 2002, Journal of medicinal chemistry.

[199]  Weidong Wang,et al.  Specific targeting and constitutive association of histone deacetylase complexes during transcriptional repression. , 2002, Genes & development.

[200]  Colin A. Johnson,et al.  Human Class I Histone Deacetylase Complexes Show Enhanced Catalytic Activity in the Presence of ATP and Co-immunoprecipitate with the ATP-dependent Chaperone Protein Hsp70* , 2002, The Journal of Biological Chemistry.

[201]  Wen‐Ming Yang,et al.  Functional Domains of Histone Deacetylase-3* , 2002, The Journal of Biological Chemistry.

[202]  Brian T Chait,et al.  The N-CoR-HDAC3 nuclear receptor corepressor complex inhibits the JNK pathway through the integral subunit GPS2. , 2002, Molecular cell.

[203]  N. Bertos,et al.  Identification of HDAC10, a novel class II human histone deacetylase containing a leucine-rich domain. , 2002, Nucleic acids research.

[204]  P. Atadja,et al.  Isolation and Characterization of a Novel Class II Histone Deacetylase, HDAC10* , 2002, The Journal of Biological Chemistry.

[205]  T. Yao,et al.  Molecular Cloning and Characterization of a Novel Histone Deacetylase HDAC10* , 2002, The Journal of Biological Chemistry.

[206]  Manfred Jung,et al.  Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. , 2002, Journal of medicinal chemistry.

[207]  J. Garin,et al.  Identification of Components of the Murine Histone Deacetylase 6 Complex: Link between Acetylation and Ubiquitination Signaling Pathways , 2001, Molecular and Cellular Biology.

[208]  S. Schreiber,et al.  Synthesis of 7200 small molecules based on a substructural analysis of the histone deacetylase inhibitors trichostatin and trapoxin. , 2001, Organic letters.

[209]  S. Leit,et al.  Design and synthesis of a novel class of histone deacetylase inhibitors. , 2001, Bioorganic & medicinal chemistry letters.

[210]  Delin Chen,et al.  Negative Control of p53 by Sir2α Promotes Cell Survival under Stress , 2001, Cell.

[211]  R. Weinberg,et al.  hSIR2SIRT1 Functions as an NAD-Dependent p53 Deacetylase , 2001, Cell.

[212]  E. Olson,et al.  Control of muscle development by dueling HATs and HDACs. , 2001, Current opinion in genetics & development.

[213]  Gurdial Singh,et al.  Synthesis of (S)-2-amino-8-oxodecanoic acid (Aoda) and apicidin A , 2001 .

[214]  Richard A. Rifkind,et al.  Cloning and characterization of a histone deacetylase, HDAC9 , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[215]  M. Guenther,et al.  The SMRT and N-CoR Corepressors Are Activating Cofactors for Histone Deacetylase 3 , 2001, Molecular and Cellular Biology.

[216]  C. Allis,et al.  Translating the Histone Code , 2001, Science.

[217]  S. Berger,et al.  Structure and function of bromodomains in chromatin-regulating complexes. , 2001, Gene.

[218]  R. Marmorstein.  Protein modules that manipulate histone tails for chromatin regulation , 2001, Nature Reviews Molecular Cell Biology.

[219]  A. Mai,et al.  3-(4-aroyl-1H-pyrrol-2-yl)-N-hydroxy-2-propenamides, a new class of synthetic histone deacetylase inhibitors. , 2001, Journal of medicinal chemistry.

[220]  G. Brosch,et al.  Histone acetylation: plants and fungi as model systems for the investigation of histone deacetylases , 2001, Cellular and Molecular Life Sciences CMLS.

[221]  A. Harel-Bellan,et al.  Histone acetylation and disease , 2001, Cellular and Molecular Life Sciences CMLS.

[222]  B. Asch,et al.  Genes, Chromatin, and Breast Cancer: An Epigenetic Tale , 2001, Journal of Mammary Gland Biology and Neoplasia.

[223]  S. Croft,et al.  The synthesis of cyclic tetrapeptoid analogues of the antiprotozoal natural product apicidin. , 2001, Bioorganic & medicinal chemistry letters.

[224]  K. Shin‐ya,et al.  Spiruchostatins A and B, novel gene expression-enhancing substances produced by Pseudomonas sp. , 2001 .

[225]  I. Grummt,et al.  Acetylation of TAFI68, a subunit of TIF‐IB/SL1, activates RNA polymerase I transcription , 2001, The EMBO journal.

[226]  J. Qin,et al.  Stable Histone Deacetylase Complexes Distinguished by the Presence of SANT Domain Proteins CoREST/kiaa0071 and Mta-L1* , 2001, The Journal of Biological Chemistry.

[227]  S. Schreiber,et al.  CoREST is an integral component of the CoREST- human histone deacetylase complex. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[228]  M. Yoshida,et al.  Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[229]  J. Torchia,et al.  A Novel Nuclear Receptor Corepressor Complex, N-CoR, Contains Components of the Mammalian SWI/SNF Complex and the Corepressor KAP-1* , 2000, The Journal of Biological Chemistry.

[230]  E. Olson,et al.  Activation of the myocyte enhancer factor-2 transcription factor by calcium/calmodulin-dependent protein kinase-stimulated binding of 14-3-3 to histone deacetylase 5. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[231]  P. Marks,et al.  Histone deacetylase 4 associates with extracellular signal-regulated kinases 1 and 2, and its cellular localization is regulated by oncogenic Ras. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[232]  E. Olson,et al.  Signal-dependent nuclear export of a histone deacetylase regulates muscle differentiation , 2000, Nature.

[233]  R A Rifkind,et al.  Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. , 2000, Cancer research.

[234]  Kristen Jepsen,et al.  Combinatorial Roles of the Nuclear Receptor Corepressor in Transcription and Development , 2000, Cell.

[235]  J. Qin,et al.  Both corepressor proteins SMRT and N‐CoR exist in large protein complexes containing HDAC3 , 2000, The EMBO journal.

[236]  R. Frye,et al.  Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins. , 2000, Biochemical and biophysical research communications.

[237]  S. Schreiber,et al.  Regulation of histone deacetylase 4 and 5 and transcriptional activity by 14-3-3-dependent cellular localization. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[238]  C. Glass,et al.  The histone deacetylase-3 complex contains nuclear receptor corepressors. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[239]  Minoru Yoshida,et al.  Active maintenance of mHDA2/mHDAC6 histone-deacetylase in the cytoplasm , 2000, Current Biology.

[240]  T. Nakayama,et al.  N-terminal Region, C-terminal Region, Nuclear Export Signal, and Deacetylation Activity of Histone Deacetylase-3 Are Essential for the Viability of the DT40 Chicken B Cell Line* , 2000, The Journal of Biological Chemistry.

[241]  James D. Winkler,et al.  Cloning and Characterization of a Novel Human Class I Histone Deacetylase That Functions as a Transcription Repressor* , 2000, The Journal of Biological Chemistry.

[242]  R. Shiekhattar,et al.  A core SMRT corepressor complex containing HDAC3 and TBL1, a WD40-repeat protein linked to deafness. , 2000, Genes & Development.

[243]  A. Bird,et al.  Histone deacetylases: silencers for hire. , 2000, Trends in biochemical sciences.

[244]  L. Guarente,et al.  Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase , 2000, Nature.

[245]  J. Robl,et al.  N-formyl hydroxylamine containing dipeptides: generation of a new class of vasopeptidase inhibitors. , 2000, Bioorganic & medicinal chemistry letters.

[246]  C. Glass,et al.  The coregulator exchange in transcriptional functions of nuclear receptors. , 2000, Genes & development.

[247]  C. Allis,et al.  The language of covalent histone modifications , 2000, Nature.

[248]  R. Evans,et al.  Isolation of a novel histone deacetylase reveals that class I and class II deacetylases promote SMRT-mediated repression. , 2000, Genes & development.

[249]  E. Miska,et al.  Nuclear receptor corepressors partner with class II histone deacetylases in a Sin3-independent repression pathway. , 2000, Genes & development.

[250]  H. Heng,et al.  HDAC4, a Human Histone Deacetylase Related to Yeast HDA1, Is a Transcriptional Corepressor , 1999, Molecular and Cellular Biology.

[251]  G Brosch,et al.  Amide analogues of trichostatin A as inhibitors of histone deacetylase and inducers of terminal cell differentiation. , 1999, Journal of medicinal chemistry.

[252]  E. Miska,et al.  MEF‐2 function is modified by a novel co‐repressor, MITR , 1999, The EMBO journal.

[253]  E. Miska,et al.  HDAC4 deacetylase associates with and represses the MEF2 transcription factor , 1999, The EMBO journal.

[254]  P. Marks,et al.  Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors , 1999, Nature.

[255]  A. Bird,et al.  Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation. , 1999, Genes & development.

[256]  T. Suzuki,et al.  Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives. , 1999, Journal of medicinal chemistry.

[257]  R. Frye,et al.  Characterization of five human cDNAs with homology to the yeast SIR2 gene: Sir2-like proteins (sirtuins) metabolize NAD and may have protein ADP-ribosyltransferase activity. , 1999, Biochemical and biophysical research communications.

[258]  A. Kumagai,et al.  Binding of 14-3-3 proteins and nuclear export control the intracellular localization of the mitotic inducer Cdc25. , 1999, Genes & development.

[259]  S. Schreiber,et al.  Three proteins define a class of human histone deacetylases related to yeast Hda1p. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[260]  N. Nomura,et al.  A New Family of Human Histone Deacetylases Related toSaccharomyces cerevisiae HDA1p* , 1999, The Journal of Biological Chemistry.

[261]  S. Horinouchi,et al.  Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase , 1999, Oncogene.

[262]  T. Tsuruo,et al.  A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[263]  A. Verdel,et al.  Identification of a New Family of Higher Eukaryotic Histone Deacetylases , 1999, The Journal of Biological Chemistry.

[264]  S. Schreiber,et al.  Chromatin deacetylation by an ATP-dependent nucleosome remodelling complex , 1998, Nature.

[265]  S. Schreiber,et al.  A role for histone deacetylase activity in HDAC1-mediated transcriptional repression. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[266]  P. Marks,et al.  A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[267]  K. Struhl.  Histone acetylation and transcriptional regulatory mechanisms. , 1998, Genes & development.

[268]  T. Richmond,et al.  Crystal structure of the nucleosome core particle at 2.8 Å resolution , 1997, Nature.

[269]  D. Reinberg,et al.  Histone Deacetylases and SAP18, a Novel Polypeptide, Are Components of a Human Sin3 Complex , 1997, Cell.

[270]  A. Wolffe.  Sinful repression , 1997, nature.

[271]  D. Schmatz,et al.  Apicidins: Novel cyclic tetrapeptides as coccidiostats and antimalarial agents from Fusarium pallidoroseum , 1996 .

[272]  S. Schreiber,et al.  Synthesis of Natural and Modified Trapoxins, Useful Reagents for Exploring Histone Deacetylase Function , 1996 .

[273]  Khan W. Li,et al.  Total Synthesis of the Antitumor Depsipeptide FR-901,228 , 1996 .

[274]  S. Wenzel,et al.  Zileuton: The First 5-Lipoxygenase Inhibitor for the Treatment of Asthma , 1996, The Annals of pharmacotherapy.

[275]  Alan P. Wolffe,et al.  Targeting Chromatin Disruption: Transcription Regulators that Acetylate Histones , 1996, Cell.

[276]  I. Kawamura,et al.  FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. III. Antitumor activities on experimental tumors in mice. , 1994, The Journal of antibiotics.

[277]  J. Fauchère,et al.  Antitumoral cyclic peptide analogues of chlamydocin , 1993, Peptides.

[278]  M. Yoshida,et al.  Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase. , 1993, The Journal of biological chemistry.

[279]  J. Baldwin,et al.  Stereospecific Synthesis of Chlamydocin , 1993 .

[280]  F. Persico,et al.  Benzothiazole hydroxy ureas as inhibitors of 5-lipoxygenase: use of the hydroxyurea moiety as a replacement for hydroxamic acid. , 1992, Journal of medicinal chemistry.

[281]  Minoru Yoshida,et al.  [Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A]. , 1990, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.

[282]  T. R. Hebbes,et al.  A direct link between core histone acetylation and transcriptionally active chromatin. , 1988, The EMBO journal.

[283]  K. Nakahara,et al.  Studies on WF-3161, a new antitumor antibiotic. , 1983, The Journal of antibiotics.

[284]  James M. Morrell,et al.  Structure-activity relationships of aryloxyalkanoic acid hydroxyamides as potent inhibitors of histone deacetylase. , 2007, Bioorganic & medicinal chemistry letters.

[285]  B. Lakowski,et al.  CoREST-like complexes regulate chromatin modification and neuronal gene expression , 2007, Journal of Molecular Neuroscience.

[286]  A. El-Osta,et al.  Will broad-spectrum histone deacetylase inhibitors be superseded by more specific compounds? , 2007, Leukemia.

[287]  E. Verdin.  HISTONE DEACETYLASES: TRANSCRIPTIONAL REGULATION AND OTHER CELLULAR FUNCTIONS , 2006 .

[288]  S. Minucci,et al.  Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer , 2006, Nature Reviews Cancer.

[289]  H. Weinmann,et al.  Recent Advances in Medicinal Chemistry of Histone Deacetylase Inhibitors , 2004 .

[290]  P. Schultz,et al.  Design, synthesis, and activity of HDAC inhibitors with a N-formyl hydroxylamine head group. , 2004, Bioorganic & medicinal chemistry letters.

[291]  F. Dequiedt,et al.  Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. , 2002, Molecular cell.

[292]  N. Bertos,et al.  Class II histone deacetylases: structure, function, and regulation. , 2001, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[293]  D. Schmatz,et al.  Broad spectrum antiprotozoal agents that inhibit histone deacetylase: structure-activity relationships of apicidin. Part 1. , 2001, Bioorganic & medicinal chemistry letters.

[294]  T. Tsuruo,et al.  Activity Synthetic Histone Deacetylase Inhibitor with Antitumor Cyclic Hydroxamic-acid-containing Peptide 31 , a Potent Updated Version , 2001 .

[295]  V. Kiermer,et al.  The emerging role of class II histone deacetylases. , 2001, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[296]  M. McVey,et al.  Sir2: an NAD-dependent histone deacetylase that connects chromatin silencing, metabolism, and aging. , 2000, Cold Spring Harbor symposia on quantitative biology.

[297]  J. Herman,et al.  Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer , 1999, Nature Genetics.

[298]  H. Wang,et al.  FR901228, Antineoplastic antibiotic , 1999 .

[299]  A. Csordás,et al.  On the biological role of histone acetylation. , 1990, The Biochemical journal.

[300]  K. Mori,et al.  Synthesis of trichostatin a, a potent differentiation inducer of friend leukemic cells, and its antipode , 1988 .

[301]  R. D. Dyer,et al.  Orally active hydroxamic acid inhibitors of leukotriene biosynthesis. , 1988, Journal of medicinal chemistry.

[302]  U. Schmidt,et al.  Amino Acids and Peptides; 551. Synthesis of Biologically Active Cyclopeptides; 71. Total Synthesis of Chlamydocin , 1986 .

[303]  D. Rich,et al.  Stereoselective synthesis and absolute configuration of epoxyketones in chlamydocin and related cyclic tetrapeptides , 1986 .